Cargando…

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma

BACKGROUND: TP53 mutations are associated with poor outcome for patients with endometrial carcinoma (EC). However, to date, there have been no studies focused on the construction of TP53 mutational status-associated signature in EC. In this study, we aim to conduct a TP53 mutation-associated prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ying, Zhao, Wancheng, Bi, Fangfang, Pan, Xue, Yin, Lili, Zhao, Chengzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280614/ https://www.ncbi.nlm.nih.gov/pubmed/35847579 http://dx.doi.org/10.1155/2022/1817339

Ejemplares similares

TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer
por: Zhang, Feng, et al.
Publicado: (2021)

Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Wu, Ying, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
por: Kim, Kyoung Min, et al.
Publicado: (2022)

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53
por: Gao, Fan, et al.
Publicado: (2023)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
por: Zhao, Xiaojuan, et al.
Publicado: (2019)

The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
por: Adamczyk-Gruszka, Olga, et al.
Publicado: (2022)

Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
por: Reske, Jake J., et al.
Publicado: (2021)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
por: Fan, Zhisong, et al.
Publicado: (2022)

TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
por: Kupryjańczyk, J, et al.
Publicado: (2004)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
por: Lyu, Haoyu, et al.
Publicado: (2019)

Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non–Small Cell Lung Cancer
por: Zhu, Lihuan, et al.
Publicado: (2023)

Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers
por: Vu, Trung, et al.
Publicado: (2023)

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
por: Feng, Juan, et al.
Publicado: (2023)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Mutational status of K- ras and TP53 genes in primary sarcomas of the heart
por: Garcia, J M, et al.
Publicado: (2000)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study
por: Syahruddin, Elisna, et al.
Publicado: (2022)

Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer
por: Wang, Ying, et al.
Publicado: (2022)

Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
por: Bi, Fangfang, et al.
Publicado: (2020)

TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients
por: Zhang, Jian, et al.
Publicado: (2022)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
por: Akahane, Tomoko, et al.
Publicado: (2022)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d5icb5ehj8rvsbec828m05ole1